Phaseline

Targets › PIM2

PIM2 (Serine/threonine-protein kinase pim-2): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression, the regulation of cap-dependent protein translation and through survival signaling by phosphorylation of a pro-apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of MYC…. (UniProt, Q9P1W9)

Open in Phaseline: the race on PIM2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ryvu TherapeuticsMEN1703 (SEL24, Dapolsertib hydrochloride)
Dual inhibitor of PIM kinases and FLT3
PIM1, PIM2, PIM3, FLT3Phase 2Non-Hodgkin Lymphoma, B-cellDec 2026
Sumitomo Pharma AmericaNuvisertib (TP-3654)
PIM kinase inhibitor
PIM1, PIM2, PIM3Phase 1MyelofibrosisApr 2027

Conditions

Non-Hodgkin Lymphoma, B-cell (1) Myelofibrosis (1)

Modalities

mixed (1), small molecule (1)

Companies

Ryvu Therapeutics (1) Sumitomo Pharma America (1)

Related targets

PIM1 (2) PIM3 (2) FLT3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.